- In March 2023, Pfizer announced a Phase 3 study evaluating its next-generation shingles vaccine candidate with enhanced immunogenicity
- In July 2022, Roche partnered with a virology research institute to accelerate development of long-acting antivirals for herpes virus infections
- In 2024, South Korea’s health authority approved a new recombinant vaccine aimed at boosting protection against herpes zoster in adults over 60. The report also highlights emerging trends such as AI-supported outbreak prediction, advancements in vaccine adjuvant technology, and integrated care models for managing acute shingles and postherpetic neuralgia.
